论文部分内容阅读
前列腺癌的治疗已经进入了肿瘤免疫治疗的时代，其中 Sipuleucel－T已经用于症状轻微的激素抵抗前列腺癌患者的治疗。其他用于前列腺癌治疗的还有免疫检查点抑制剂（ Ipilimumab ）、树突状细胞疫苗（DCVax）以及肿瘤抗原（GVAXΞ和 PROSTVAC－VF）等，均在早期临床试验中显示出乐观的应用前景，并均已进入临床Ⅲ期研究。因此，前列腺癌的免疫治疗是可行的、有效的，值得进一步探索和研究。“,”The treatment approach of prostate cancer has already entered the era of immunotherapy . Sipuleucel-T is the first immunotherapeutic drug for the treatment of light-symptomatic castrate-resistant pros-tate cancer.The other immunological therapeutics under clinical development are immune checkpoint inhibi-tor (Ipilimumab),dendritic cell vaccines(DCVax),and tumor vaccine (GVAX and PROSTVAC-VF),which have shown promising potential in early phase clinical studies ,and have entered phaseⅢclinical study.Immu-notherapy for prostate cancer is feasible and effective,worthy of further exploration and development.